Current Progress and Future Perspectives of Immune Checkpoint Inhibitors in Biliary Tract Cancer
Poshita-Kumari Seesaha,1,* Kang-Xin Wang,2,* Guo-Qun Wang,2 Ting-Yun Cui,2 Feng-Jiao Zhao,1 Lan-Lan Pan,1 Xiang-Cheng Li,3 Yong-Qian Shu,1 Xiao-Feng Chen1,2 1Department of Oncology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, 210029, People’s Republic of China;...
Main Authors: | Seesaha PK, Wang KX, Wang GQ, Cui TY, Zhao FJ, Pan LL, Li XC, Shu YQ, Chen XF |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2021-03-01
|
Series: | OncoTargets and Therapy |
Subjects: | |
Online Access: | https://www.dovepress.com/current-progress-and-future-perspectives-of-immune-checkpoint-inhibito-peer-reviewed-article-OTT |
Similar Items
-
PD-L1, TMB, MSI, and Other Predictors of Response toImmune Checkpoint Inhibitors in Biliary Tract Cancer
by: Alessandro Rizzo, et al.
Published: (2021-02-01) -
Immunotherapy in Advanced Biliary Tract Cancers
by: Alice Boilève, et al.
Published: (2021-03-01) -
Integrative clinical and molecular analysis of advanced biliary tract cancers on immune checkpoint blockade reveals potential markers of response
by: Jingjing Li, et al.
Published: (2020-08-01) -
Chemotherapy for Biliary Tract Cancer in 2021
by: Takashi Sasaki, et al.
Published: (2021-07-01) -
mTOR Inhibitors in Advanced Biliary Tract Cancers
by: Chao-En Wu, et al.
Published: (2019-01-01)